` SNGX (Soligenix Inc) vs S&P 500 Comparison - Alpha Spread

SNGX
vs
S&P 500

Over the past 12 months, SNGX has underperformed S&P 500, delivering a return of -48% compared to the S&P 500's 9% growth.

Stocks Performance
SNGX vs S&P 500

Loading
SNGX
S&P 500
Add Stock

Performance Gap
SNGX vs S&P 500

Loading
SNGX
S&P 500
Difference
www.alphaspread.com

Performance By Year
SNGX vs S&P 500

Loading
SNGX
S&P 500
Add Stock

Competitors Performance
Soligenix Inc vs Peers

S&P 500
SNGX
ABBV
AMGN
GILD
VRTX
Add Stock

Soligenix Inc
Glance View

Market Cap
5.7m USD
Industry
Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The firm is focused on developing products to treat rare diseases. The firm operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of HyBryte (SGX301 or synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions segment includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The firm's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203).

SNGX Intrinsic Value
2.321 USD
Undervaluation 23%
Intrinsic Value
Price
Back to Top